Bart C. Kuenen

1.6k citations

31 papers · 1.2k indexed · h-index 17

Internal Medicine top 5%
Oncology top 5%
- Cancer Treatment and Pharmacology 8
- Colorectal Cancer Treatments and Studies 5
- HER2/EGFR in Cancer Research 3
Hematology top 5%
- Multiple Myeloma Research and Treatments 3
Cancer Research top 10%
Pulmonary and Respiratory Medicine top 10%
- Lung Cancer Treatments and Mutations 6
Molecular Biology
- Angiogenesis and VEGF in Cancer 6
- PI3K/AKT/mTOR signaling in cancer 4
Genetics
- Chronic Lymphocytic Leukemia Research 2

Co-authors: Herbert M. Pinedo Giuseppe Giaccone Marcel Levi Klaas Hoekman Victor W.M. van Hinsbergh A.K. Kakkar Joost C.M. Meijers Rita Ruijter
Cited by: Internal Medicine Oncology Hematology
Partner nations: Netherlands United States Germany

In The Last Decade

Bart C. Kuenen

30 papers receiving 1.2k citations

Peers

Countries citing papers authored by Bart C. Kuenen

Since Specialization

Citations

This map shows the geographic impact of Bart C. Kuenen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart C. Kuenen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart C. Kuenen more than expected).

Fields of papers citing papers by Bart C. Kuenen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bart C. Kuenen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart C. Kuenen. The network helps show where Bart C. Kuenen may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Bart C. Kuenen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Bart C. Kuenen Line = papers co-authored together Bart C. Kuenen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Immune checkpoint inhibitor–associated myocarditis Thamara E. Osinga,Sjoukje F. Oosting,Peter van der Meer,Rudolf A. de Boer,Bart C. Kuenen,Abraham Rutgers,Lothar Bergmann,Thijs H. Oude Munnink,Mathilde Jalving,Michel van Kruchten	2022	13
2	Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours Stan B. Kaye,Steinar Aamdal,Richard D. Jones,Gilles Freyer,Éric Pujade-Lauraine,Elisabeth G.E. de Vries,Jorge Barriuso,Shahneen Sandhu,Daniel S.W. Tan,V Hartog,Bart C. Kuenen,Rita Ruijter,Gunnar B. Kristensen,Marta Nyakas,Sophie Barrett,Wendy Burke,D Pietersma,Melissa K. Stuart,Ugochi Emeribe,Epie Boven	2012	29
3	A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies Bart C. Kuenen,Petronella O. Witteveen,Rita Ruijter,Giuseppe Giaccone,Aruna Dontabhaktuni,Floyd E. Fox,Terry Katz,Hagop Youssoufian,Junming Zhu,Eric K. Rowinsky,Emile E. Voest	2010	66
4	Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer A.-R. Hanauske,Michael Lahn,Luna Musib,K. Weigang-Köhler,Emine Yılmaz,T. Graefe,Bart C. Kuenen,D. Thornton,P. McNealy,Giuseppe Giaccone	2009	21
5	Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC) Elisa Giovannetti,Richard J. Honeywell,Axel R. Hanauske,Christina Tekle,Bart C. Kuenen,J. Sigmond,Giuseppe Giaccone,Godefridus J. Peters	2009	13
6	Defective Differentiation of Myeloid and Plasmacytoid Dendritic Cells in Advanced Cancer Patients is not Normalized by Tyrosine Kinase Inhibition of the Vascular Endothelial Growth Factor Receptor Hester van Cruijsen,Klaas Hoekman,Anita G.M. Stam,Alfons J.M. van den Eertwegh,Bart C. Kuenen,Rik J. Scheper,Giuseppe Giaccone,Tanja D. de Gruijl	2007	24
7	Comparison of enzastaurin pharmacokinetics and safety in the once daily (QD) and twice daily (BID) dose regimens: A phase I study Axel-Rainer Hanauske,Luna Musib,K. Weigang-Köhler,Emine Yılmaz,T. Graefe,Bart C. Kuenen,D. Thornton,Michael Lahn,Christelle Darstein,Giuseppe Giaccone	2007	1
8	A Phase I Safety and Pharmacologic Study of a Twice Weekly Dosing Regimen of the Oral Taxane BMS-275183 Linda E. Bröker,Stephan A. Veltkamp,Elisabeth I. Heath,Bart C. Kuenen,Helen Gall,Ludovic Astier,Susan Parker,L. Kayitalire,Patricia LoRusso,Jan H.M. Schellens,Giuseppe Giaccone	2007	21
9	A phase I study of IMC-11F8, a fully human anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors. Interim results Bart C. Kuenen,Els O. Witteveen,Rita Ruijter,Annette Ervin‐Haynes,Manuel L. R. Tjin‐A‐Ton,Floyd E. Fox,Chongyang Ding,Giuseppe Giaccone,Emile E. Voest	2006	7
10	Pharmacokinetic interaction and safety of enzastaurin and pemetrexed in patients with advanced or metastatic cancer A.-R. Hanauske,K. Weigang Koehler,Emel Yilmaz,T. Graefe,Bart C. Kuenen,D. Thornton,Michael Lahn,Christelle Darstein,Luna Musib,G. Guiseppe	2006	9
11	Phase I Trial with BMS-275183, a Novel Oral Taxane with Promising Antitumor Activity Linda E. Bröker,Filip De Vos,Cees J. van Groeningen,Bart C. Kuenen,Helen Gall,Michael H. Woo,Maurizio Voi,Jourik A. Gietema,Elisabeth G.E. de Vries,Giuseppe Giaccone	2006	19
12	A patient with a VEGF and endostatin producing gastrointestinal autonomic nerve tumour Annemarie H.G. Hansma,Yvette van Hensbergen,Bart C. Kuenen,P. J. van Diest,Roeland Hanemaaijer,S. Meijer,Herbert M. Pinedo,K. Hoekman	2004	3
13	Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Bart C. Kuenen,Josep Tabernero,José Baselga,Franco Cavalli,Elisabeth Pfanner,Pierfranco Conté,S. Seeber,Srinivasan Madhusudan,G. Deplanque,H. van der Wal- Huisman,P. Scigalla,Klaas Hoekman,Adrian L. Harris	2003	103
14	Potential Role of Platelets in Endothelial Damage Observed During Treatment With Cisplatin, Gemcitabine, and the Angiogenesis Inhibitor SU5416 Bart C. Kuenen,Marcel Levi,Joost C.M. Meijers,Victor W.M. van Hinsbergh,Johannes Berkhof,A.K. Kakkar,K. Hoekman,Herbert M. Pinedo	2003	91
15	Analysis of Prothrombotic Mechanisms and Endothelial Perturbation during Treatment with Angiogenesis Inhibitors Bart C. Kuenen	2003	22
16	Analysis of Coagulation Cascade and Endothelial Cell Activation During Inhibition of Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Pathway in Cancer Patients Bart C. Kuenen,Marcel Levi,Joost C.M. Meijers,A.K. Kakkar,Victor W.M. van Hinsbergh,P.J. Kostense,Herbert M. Pinedo,Klaas Hoekman	2002	123
17	Effect of Providing Cancer Patients With the Audiotaped Initial Consultation on Satisfaction, Recall, and Quality of Life: A Randomized, Double-Blind Study L.M.L. Ong,Marja Visser,Frits B. Lammes,Jacobus van der Velden,Bart C. Kuenen,J.C.J.M. de Haes	2000	109
18	Non-islet-cell tumour induced hypoglycaemia: a case report and review of literature Bart C. Kuenen,J VANDOORN,PH Slee	1996	8
19	Relative increase of inflammatory CD4+ T cells in the cerebrospinal fluid of multiple sclerosis patients and control individuals Francien T.M. Rotteveel,Bart C. Kuenen,Ingrid Kokkelink,Anthony Meager,C.J. Lucas	1990	9
20	Clonal analysis of functionally distinct human CD4+ T cell subsets. Francien T.M. Rotteveel,Ingrid Kokkelink,René A. W. van Lier,Bart C. Kuenen,Anthony Meager,Frank Miedema,C.J. Lucas	1988	82

About Bart C. Kuenen

Bart C. Kuenen is a scholar working on Oncology, Hematology and Hepatology, having authored 31 papers that have together received 1.2k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (8 papers), Angiogenesis and VEGF in Cancer (6 papers), Lung Cancer Treatments and Mutations (6 papers), Colorectal Cancer Treatments and Studies (5 papers), PI3K/AKT/mTOR signaling in cancer (4 papers), Multiple Myeloma Research and Treatments (3 papers), HER2/EGFR in Cancer Research (3 papers) and Chronic Lymphocytic Leukemia Research (2 papers). The work is most often cited by research in Internal Medicine (132 citations), Oncology (519 citations) and Hematology (159 citations). Bart C. Kuenen has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Herbert M. Pinedo, Giuseppe Giaccone, Marcel Levi, Klaas Hoekman, Victor W.M. van Hinsbergh, A.K. Kakkar, Joost C.M. Meijers, Rita Ruijter, K. Hoekman and Marja Visser.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact